Journal: Cell

Article Title: Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

doi: 10.1016/j.cell.2021.06.020

Figure Lengend Snippet: Neutralization by vaccine serum and mapping variants in antigenic space For the Pfizer vaccine, serum (n = 25) was taken 7–17 days following the second dose of the Pfizer-BioNTech vaccine. For the AstraZenca vaccine, serum was taken 14 or 28 days following the second dose of the Oxford-AstraZeneca vaccine (n = 25). (A) NT50 titers of Pfizer-BioNTech serum against B.1.617.1-B pseudovirus. (B) FRNT50 titers of Oxford-AstraZeneca serum against B.1.617.1-B pseudovirus. (C) FRNT50 titers of Pfizer-BioNTech serum against B.1.617.2 virus. (D) FRNT50 against of Oxford-AstraZeneca serum against B.1.617.2 virus. (A–D) Comparison is made with Victoria pseudo virus (A and B) or wild-type Victoria, B.1.1.7, B.1.351, and P.1 (filled squares), reported previously ( Supasa et al., 2021 ; Zhou et al., 2021 ; Dejnirattisai et al., 2021b ) (C and D). Subsequent panels analyze responses following a single dose of Pfizer vaccine. Serum (n = 20) was taken 28 or 70 days following the first dose of the Pfizer-BioNTech vaccine. (E and F) Comparison of FRNT50 titers for individual samples obtained 28 or 70 days after the first dose against Victoria or B.1.617.2. (G and H) Comparison of percent virus neutralization at serum dilution of 1:20 against SARS-CoV-2 Victoria and B.1.617.2 strains. Mean values are indicated above each column. (E–H) Mann-Whitney unpaired test was used for the analysis in (E) and (G). Wilcoxon matched-pairs signed rank test was used for the analysis in (F) and (H). (I) Map of variants in antigenic space. Wall-eyed stereo pair plots show output of principal-component analysis converting serum/virus strain pair neutralization capacities to antigenic space. Circle size denotes depth along the axis connecting the reader’s nose to the origin. See also . (J) Positions and charge effects of RBD mutations found in variants of concern. Shown is an incoming ACE2 view of the surface of the RBD, with the footprint of ACE2 shown in green and mutations occurring in variants, including B.1.1.7, P.1, P.1.351, B.1.617.1, and B.1.617.2, shown in a range of other colors.

Article Snippet: For B.1.617.2, titers were reduced 2.5-fold (p < 0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum ( C) and 4.3-fold (p < 0.0001) for the Oxford-AstraZeneca vaccine ( D).

Techniques: Neutralization, MANN-WHITNEY

Journal: Cell

Article Title: Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

doi: 10.1016/j.cell.2021.06.020

Figure Lengend Snippet: Neutralization curves against SARS-CoV-2 pseudotyped lentiviruses expressing full-length S of Victoria and B.1.617.1 strains by serum from 25 recipients of the Pfizer-BioNTech vaccine and Oxford-AstraZeneca vaccine, related to FRNT50 titers given in .

Article Snippet: For B.1.617.2, titers were reduced 2.5-fold (p < 0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum ( C) and 4.3-fold (p < 0.0001) for the Oxford-AstraZeneca vaccine ( D).

Techniques: Neutralization, Expressing

Journal: Cell

Article Title: SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

doi: 10.1016/j.cell.2021.12.046

Figure Lengend Snippet:

Article Snippet: Serum from Pfizer-vaccinated individuals , University of Oxford , N/A.

Techniques: Virus, Bacteria, Clinical Proteomics, Recombinant, Saline, Modification, Expressing, Plasmid Preparation, Software, Titration, Buffer Exchange, Crystallization Assay, Imaging